Abstract
Airborne transmission is the most efficient and widespread route of viral spread, posing a significant challenge in controlling major infectious diseases such as COVID-19 and influenza. In microgravity environment, such as the International Space Station (ISS), this mode of transmission requires heightened vigilance and preventive measures due to the prolonged suspension of virus-laden particles, which increases the risk of infection. Using the COVID Airborne Risk Assessment (CARA) tool, we assess the risk of airborne transmission of respiratory viruses in microgravity by simulating the emission, dispersion, and inhalation of virus-laden particles. Our findings show that the unique conditions of microgravity allow these particles to remain airborne for significantly longer periods compared to Earth, leading to a 286-fold increase in virus concentration in the air, resulting in nearly twice the probability of infection for a susceptible host. We also evaluated the effectiveness of preventive measures, and found that facemasks can reduce the risk by up to 23% while continuous HEPA filtration at five air changes per hour proves crucial for managing air quality and minimizing infection risks by reducing airborne virus concentration at 99.79%. However, when simulated the infection risk by accounting the spaceflight-induced immune suppression, we found that the infection probability increased by 12% in the condition that viral load in infected host increase for 8-fold and absence of protective measures. Although facemasks and air filtration help mitigate the risk, their effectiveness diminishes when the viral load carrying by host is high. Enhancing host immunity through vaccination or other interventions is vital, potentially reducing infection probability by up to 14.17% when combined with HEPA filtration. These findings highlight the need for robust mitigation strategies to safeguard the health of astronauts against airborne pathogens during future space missions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has received funding support from the NSRF via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation (PMU-B) [grant number B13F660122].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
